Literature Modeling and Model-Based Meta Analysis — Selected References
Articles
Corrigan BW et al. Model-Based Meta-Analyses vs. Clinical Impressionism: Challenges and Rewards. AAPS Newsmagazine, September 2007, pps. 26-27.
Ebling W, Fredrickson J, Rutkin A. The Role of Literature Models To Support Strategic Decision-Making in Clinical Drug Development. Pharsight Insights, Summer 2006.
Korsan B, Dykstra K, Pullman W. Transparent Trade-Offs: A Clinical Utility Index (CUI) Openly Evaluates a Product's Attributes ? and Chance of Success. Pharmaceutical Executive. March 2005.
Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D. Model-Based Development of Gemcabene, a New Lipid-Altering Agent. AAPS Journal. 2005; 7(3).
Presentations
Kastrissios H. Communicating the Value of Pharmacodynamic Modeling in Drug Development. [invited presentation]. Presented at: Association of Regulatory and Clinical Scientists (ARCS) 17th Annual Congress; May 28-30, 2008; Sydney, Australia.
Dykstra K, Hodge L, Carrothers TJ, Korsan B. Linking Modeling & Simulation, Decision Analysis, and the Technology of Drug Formulation. [poster presentation]. American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson, Arizona.
Gillespie B. Model-Based Meta-Analysis for Integration of Data from Multiple Sources. Modeling and Simulation online webinar. February 15, 2006. Available at www.pharsight.com.
Powell R. FDA Experience with End of Phase IIa Meeting: An Attempt to Improve Drug Development Decisions. Presented at Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Sciences. November 14, 2005.
Hermann D, Wang W, Falcoz C, Hartman D, Mandema J. Strategies to Improve Model-Based Decision-Making During Clinical Development [poster]. Presented at: Annual Meeting of the Population Approach Group in Europe (PAGE); June 2005; Pamplona, Spain. Reprinted courtesy of PAGE.